Less than two months after closing a $100m series C round, the Dundee spinout has raised $225m in a series D led by SoftBank Vision Fund 2.
Exscientia, a UK-based drug discovery technology spinout of University of Dundee, secured $225m in series D financing yesterday led by SoftBank Vision Fund 2, a vehicle for telecoms conglomerate SoftBank.
Pharmaceutical firms Novo and Bristol Myers Squibb also took part in the round, as did funds managed by BlackRock, GT Healthcare Capital, Marshall Wace, Pivotal BioVenture Partners, Laurion Capital, Hongkou and Abu Dhabi state-owned Mubadala Investment Company.
SoftBank has committed an additional $300m in equity that can be drawn at…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
